MetLife Investment Management LLC Sells 543 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• MetLife Investment Management LLC reduced its stake in Regeneron Pharmaceuticals by 1.9%, ending the quarter with a total of 27,697 shares worth approximately $17.57 million.
• Regeneron's quarterly earnings report revealed an EPS of $12.89, significantly beating the consensus estimate of $8.43 and showcasing a year-over-year revenue growth of 3.6%.
• The company recently announced a quarterly dividend of $0.88 per share, translating to an annual yield of 0.6%, with the dividend set to be paid to shareholders on September 3rd.

MetLife Investment Management LLC trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1.9% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 27,697 shares of the biopharmaceutical company's stock after selling 543 shares during the period. MetLife Investment Management LLC's holdings in Regeneron Pharmaceuticals were worth $17,566,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of REGN. Pinney & Scofield Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $25,000. E Fund Management Hong Kong Co. Ltd. lifted its position in shares of Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 31 shares in the last quarter. Costello Asset Management INC purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at about $27,000. Tompkins Financial Corp purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at about $32,000. Finally, Curat Global LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at about $32,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Royal Bank Of Canada lifted their price objective on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a research report on Monday, August 4th. JPMorgan Chase & Co. lowered their price objective on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research report on Monday, June 9th. Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Guggenheim boosted their price target on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Finally, BMO Capital Markets boosted their price target on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a report on Monday, August 4th. Three analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $817.67.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded up $1.09 on Friday, reaching $580.70. The company's stock had a trading volume of 574,305 shares, compared to its average volume of 1,042,369. The stock's fifty day simple moving average is $557.26 and its 200-day simple moving average is $587.56. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,210.97. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $61.55 billion, a price-to-earnings ratio of 14.63, a price-to-earnings-growth ratio of 1.93 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. During the same period last year, the firm posted $11.56 earnings per share. Regeneron Pharmaceuticals's revenue for the quarter was up 3.6% compared to the same quarter last year. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is currently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.